propagermanium has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kleemann, R; Mulder, P; van den Hoek, AM | 1 |
1 other study(ies) available for propagermanium and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Arginase; CD11 Antigens; Chemokine CCL2; Diet, High-Fat; Germanium; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organometallic Compounds; Propionates; Receptors, CCR2 | 2017 |